查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606727

扩大性心肌病药物市场：按药物类别、治疗类型、给药途径、最终用户、分销管道划分 - 全球预测 2025-2030

Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年扩大性心肌病药物市值为4.215亿美元，预计2024年将达到4.5676亿美元，复合年增长率为7.79%，2030年将达到7.1265亿美元，预计将达到1000万美元。

扩大性心肌病（DCM）治疗是指旨在控制和缓解扩大性心肌病（一种以心臟扩大和衰弱为特征的心肌疾病）的标靶治疗策略和药物。全球心臟病患病率的不断上升、人口老化以及需要专门治疗来改善患者的生活品质和生存率，都强调了对治疗扩大性心肌病的药物的需求。这些治疗剂的应用通常包括药物干预，例如 ACE 抑制剂和β阻断剂，在某些情况下，还包括使用机械装置和心臟移植。最终用途范围主要包括专门从事高级心臟护理的医院、诊所和学术医疗中心。关键的市场成长要素包括医疗设备的技术进步、医疗保健支出的增加以及心肌病认知和诊断率的提高。专注于基因疗法和干细胞疗法等新型疗法的研发活动的活性化为市场参与企业扩大其产品组合提供了潜在机会。新兴市场的地理扩张，加上策略联盟和伙伴关係，也提供了开拓开拓市场的机会。然而，高昂的治疗成本、严格的监管条件和潜在的副作用等限制因素可能会对市场成长构成重大挑战。此外，心肌病复杂的病理生理学使得治疗方法的开发变得困难，并且需要大量的研发投资。为了促进创新和业务成长，基因组和生物标记研究、精准医疗、非侵入性诊断和远端医疗等领域可能会在 DCM 治疗领域带来重大突破。市场是充满活力和竞争的，因此公司必须保持敏捷和创新，并且必须专注于以患者为中心的方法以获得竞争优势。持续监控临床试验、技术进步和法规对于相关人员在这复杂的环境中取得成功至关重要。

主要市场统计
基准年[2023] 4.215 亿美元
预测年份 [2024] 4.5676亿美元
预测年份 [2030] 71265万美元
复合年增长率（%） 7.79%

市场动态：快速发展的扩大性心肌病药物市场的关键市场洞察

供应和需求的动态交互作用正在改变扩大性心肌病药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 心血管疾病的盛行率和有效治疗的需求
    • 以疾病的早期诊断和治疗为导向
    • 政府提高心血管疾病意识的措施和计划
  • 市场限制因素
    • 扩大性心肌病药物高成本
  • 市场机会
    • 精准医学在扩大性心肌病治疗的应用
    • 持续研发治疗扩大性心肌病的有效药物和治疗方法
  • 市场挑战
    • 扩大性心肌病治疗药物相关的副作用

波特五力：驾驭扩大性心肌病药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解扩大性心肌病药物市场的外部影响

外部宏观环境因素在塑造扩大性心肌病药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解扩大性心肌病治疗药物市场的竞争状况

对扩大性心肌病药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位扩大性心肌病药物市场供应商的绩效评估

FPNV定位矩阵是评估扩大性心肌病药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划扩大性心肌病药物市场的成功之路

对于想要加强在全球市场的影响力的公司来说，扩大性心肌病药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病的盛行率和有效治疗的需求
      • 疾病的早​​期诊断和治疗趋势
      • 政府提高心血管疾病意识的措施和计划
    • 抑制因素
      • 扩大性心肌病药物高成本
    • 机会
      • 精准医学在扩大性心肌病治疗的应用
      • 持续研发治疗扩大性心肌病的有效药物和治疗方法
    • 任务
      • 扩大性心肌病治疗药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别扩大性心肌病药物市场

  • 醛固酮拮抗剂
  • 血管收缩素II受体阻断剂
  • 血管收缩素转化酵素(ACE) 抑制剂
  • β受体阻断剂

第七章依治疗类型扩大性心肌病药物市场

  • 心臟去颤器
  • 心臟泵
  • 植入式装置
  • 药物治疗

第八章扩大性心肌病药物市场：依给药途径

  • 口服
  • 胃肠外的

第九章扩大性心肌病药物市场：依最终用户分类

  • 医院
  • 调查机构
  • 专科诊所

第10章扩大性心肌病药物市场：依分销管道分类

  • 医院药房
  • 网路药房
  • 零售药房

第十一章北美和南美扩大性心肌病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区扩大性心肌病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲扩大性心肌病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • CH Boehringer Sohn AG & Co. KG
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline（GSK）
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • The Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals
  • Viatris Inc.
Product Code: MRR-8E22B61932B4

The Dilated Cardiomyopathy Therapeutics Market was valued at USD 421.50 million in 2023, expected to reach USD 456.76 million in 2024, and is projected to grow at a CAGR of 7.79%, to USD 712.65 million by 2030.

Dilated Cardiomyopathy (DCM) Therapeutics pertains to the targeted treatment strategies and medications aimed at managing and mitigating the condition of dilated cardiomyopathy, a heart muscle disease characterized by an enlarged and weakened heart. The necessity of DCM therapeutics is underscored by the increasing prevalence of heart diseases globally, rising aging populations, and the need for specialized treatments that improve quality of life and survival rates for patients. Application of these therapeutics typically involves pharmacological interventions such as ACE inhibitors, beta-blockers, and in some cases, the use of mechanical devices or even heart transplants. The end-use scope primarily includes hospitals, clinics, and academic medical centers dedicated to advanced cardiac care. Key market growth factors include technological advancements in medical devices, increasing healthcare expenditure, and growing awareness and diagnosis rates of cardiomyopathies. Rising R&D activities focused on novel therapies such as gene and stem cell therapy offer potential opportunities for market players to expand their portfolio. Geographical expansion in emerging markets, coupled with strategic collaborations and partnerships, also present opportunities to capitalize on untapped markets. However, limitations such as high costs of treatment, strict regulatory landscapes, and the potential for adverse drug reactions can pose significant challenges to market growth. Moreover, the complex pathophysiology of cardiomyopathies makes treatment development challenging, requiring significant R&D investments. To foster innovation and business growth, areas like genomic and biomarker research, precision medicine, non-invasive diagnostic methods, and telemedicine could yield substantial breakthroughs in the field of DCM therapeutics. The market is dynamic and competitive, requiring companies to stay agile and innovative, focusing on patient-centric approaches to gain a competitive edge. Continuous monitoring of clinical trials, technological advancements, and regulations will be crucial for stakeholders aiming to navigate and succeed in this complex landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 421.50 million
Estimated Year [2024] USD 456.76 million
Forecast Year [2030] USD 712.65 million
CAGR (%) 7.79%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dilated Cardiomyopathy Therapeutics Market

The Dilated Cardiomyopathy Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cardiovascular diseases and the need for effective treatments
    • Inclination toward early diagnosis and treatment of diseases
    • Government initiatives and programs to raise awareness regarding cardiovascular diseases
  • Market Restraints
    • High cost of dilated-cardiomyopathy therapeutics
  • Market Opportunities
    • Applications of precision medicine in the management of dilated cardiomyopathy
    • Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
  • Market Challenges
    • Side effects associated with the dilated-cardiomyopathy medications

Porter's Five Forces: A Strategic Tool for Navigating the Dilated Cardiomyopathy Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dilated Cardiomyopathy Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dilated Cardiomyopathy Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dilated Cardiomyopathy Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dilated Cardiomyopathy Therapeutics Market

A detailed market share analysis in the Dilated Cardiomyopathy Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dilated Cardiomyopathy Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dilated Cardiomyopathy Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dilated Cardiomyopathy Therapeutics Market

A strategic analysis of the Dilated Cardiomyopathy Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dilated Cardiomyopathy Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug class, market is studied across Aldosterone antagonists, Angiotensin II Receptor Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, and Beta-blockers.
  • Based on Treatment Type, market is studied across Cardioverter-Defibrillators, Heart Pumps, Implantable Devices, and Medication.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
      • 5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dilated Cardiomyopathy Therapeutics Market, by Drug class

  • 6.1. Introduction
  • 6.2. Aldosterone antagonists
  • 6.3. Angiotensin II Receptor Blockers
  • 6.4. Angiotensin-converting enzyme (ACE) Inhibitors
  • 6.5. Beta-blockers

7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Cardioverter-Defibrillators
  • 7.3. Heart Pumps
  • 7.4. Implantable Devices
  • 7.5. Medication

8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Dilated Cardiomyopathy Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes
  • 9.4. Specialty Clinics

10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Dilated Cardiomyopathy Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Amicus Therapeutics
  • 4. Astellas Pharma Inc
  • 5. AstraZeneca plc
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. BioMarin Pharmaceutical Inc
  • 9. C.H. Boehringer Sohn AG & Co. KG
  • 10. Daiichi Sankyo Company, Limited
  • 11. Eli Lilly and Company
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline (GSK)
  • 14. Johnson & Johnson Services, Inc.
  • 15. Kyowa Kirin Co, Ltd
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Regeneron Pharmaceuticals, Inc.
  • 20. Roche Holding AG
  • 21. Sanofi S.A.
  • 22. Sarepta Therapeutics
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. The Bristol-Myers Squibb Company
  • 25. The Takeda Pharmaceutical Company Limited
  • 26. Vertex Pharmaceuticals
  • 27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023